Human papillomavirus (HPV) 16 antibodies at diagnosis of HPV-related oropharyngeal cancer and antibody trajectories after treatment

Infection with human papillomavirus (HPV) is the primary cause of oropharyngeal squamous cell cancer (OPC) in the United States [1]. Following treatment, HPV-driven oropharyngeal cancer (HPV-OPC) has good survival, with a 5-year survival rate of 82% [2–4]. While recurrence risk remains low among HPV-OPC [5–7], current standard of care surveillance includes intensive post-therapy monitoring that could include physical exam, fiberoptic examinations, and radiologic imaging procedures. These procedures are associated with significant time, resources, and additional costs.

http://ift.tt/2lQPo6G